Share Your LIVMARLI Story

Your Journey Matters

Whether you or your loved one is navigating life with Alagille syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC), your experience is unique—and your story could make a real impact. If you're currently taking LIVMARLI, or a parent or caregiver of someone who is, Mirum invites you to share your story and experience with LIVMARLI. Sharing your story not only celebrates your journey, but also helps others feel informed and supported.

Hear from Abby and Jay about why they choose to share their LIVMARLI story:

“I’ve struggled with cholestatic pruritis my whole life. My journey has felt like a rollercoaster at times, but I'm grateful for it. Now that I'm older, I have the freedom to make important healthcare decisions on my own. I share my story in hopes that I can inspire others my age to do the same and find a treatment that works for them.”

Taking LIVMARLI since 2023

“I choose to share our story because while the diagnosis can feel isolating, the journey doesn’t have to be. As a dad, I hope my voice encourages more fathers to share their stories too, because every perspective matters.”

Care partner to son, Finley, who has
been taking LIVMARLI since 2022

Use the form below to tell your story in your own words.

Please avoid including personal medical details or information about others without their consent.

^*Required

First Name(Required)

Last Name(Required)

Email(Required)

Phone Number(Required)

Confirm Phone Number(Required)

Select a topic(Required)

Your story(Required)

Prior to submitting your information, please review and acknowledge the following:

Consent & Privacy Acknowledgement

By submitting your information, you acknowledge and agree to the following:

You are voluntarily providing personal information and/or health-related experiences related to Alagille syndrome (ALGS) or Progressive Familial Intrahepatic Cholestasis (PFIC), and your/your loved one’s experience with LIVMARLI (maralixibat).
You understand that your submission may include sensitive information and that it may be reviewed, edited for clarity or length, and used by Mirum Pharmaceuticals and its partners for potential publication on LIVMARLI websites, social media, educational materials, and other communications.
You confirm that you have obtained permission to share information about any other individuals included in your story (e.g., a child, spouse, or caregiver).
You understand that submitting a story does not guarantee that it will be published.

Mirum Pharmaceuticals will handle your information in accordance with its Privacy Policy and applicable privacy regulations, including HIPAA where applicable.

Terms & Conditions Acknowledgement

By checking the box below and submitting your information, you:

Agree to Mirum Pharmaceuticals’ Terms of Use and Privacy Policy.
Grant Mirum Pharmaceuticals a royalty-free, worldwide, perpetual license to use, reproduce, publish, and display the content you submit, in whole or in part, in connection with LIVMARLI communications.
Confirm that your submission is truthful and based on your/your loved one’s own experience.
Understand that Mirum may contact you for additional permissions, clarification, or follow-up before your story is published.

Consent & Privacy Acknowledgment and Terms & Conditions(Required)

I have read and agree to the Consent & Privacy Acknowledgment and Terms & Conditions.

Age and residency certification(Required)

I certify that I am 18 years of age or older and am a resident of the United States.

Research opt-in

Opt in to participate in future caregiver and patient research from Mirum Pharmaceuticals.

IMPORTANT SAFETY INFORMATION

INDICATION

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients who are 3 months of age and older with Alagille syndrome.

It is not known if LIVMARLI is safe and effective in children with Alagille syndrome who are under 3 months of age. It is not known if LIVMARLI is safe and effective in adults who are 65 years of age and older.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Liver injury. Changes in certain liver tests are common in patients but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests and physical exams before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:
- nausea or vomiting
- your skin or the white part of your eye turns yellow
- dark or brown urine
- pain on the right side of the stomach (abdomen)
- fullness, bloating, or fluid in your stomach area (ascites)
- loss of appetite
- bleeding or bruising more easily than normal, including vomiting blood
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea and stomach pain during treatment. Diarrhea can also cause the loss of too much body fluid (severe dehydration). Your health care provider may advise you to monitor for new or worsening stomach problems, including stomach pain, diarrhea, blood in your stool, or vomiting. Tell your health care provider right away if you have any new or worsening signs or symptoms of stomach and intestinal problems, including:
- diarrhea
- more frequent bowel movements than usual
- stools that are black, tarry, or sticky, or have blood or mucous
- severe stomach-area pain or tenderness
- vomiting
- urinating less often than usual
- dizziness
- headache
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment, and may monitor for bone fractures and bleeding, which are common side effects.

Tell your health care provider about all medicines that you take. LIVMARLI may interact with other medicines. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

Your health care provider may change your dose, or temporarily or permanently stop treatment if you have certain side effects.

These are not all of the possible side effects of LIVMARLI. For more information, ask your health care provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information and Instructions for Use, for LIVMARLI.